What's actually known about saw palmetto, pygeum, and BPH.
The research behind every ingredient in Walter's, in plain English. Print this page if you want to bring it to your urologist.
The condition
Benign prostatic hyperplasia (BPH) is age-related enlargement of the prostate gland. By 60, more than half of US men have it. By 70, around 80%. The gland grows, presses on the urethra, and a man wakes up at 4 a.m. needing the bathroom — what urologists call nocturia. It's not a disease, exactly. It's what an aging prostate does.
The standard medical responses are alpha-blockers (Flomax, tamsulosin), 5-alpha-reductase inhibitors (Proscar, Avodart, finasteride, dutasteride), and surgery (TURP, laser ablation). Each has trade-offs that drive a lot of men to look for a third option.
Saw palmetto — the lead
Serenoa repens — saw palmetto — is a small palm native to the southeast US. The berry has been used for prostate complaints in traditional medicine for over a hundred years. European urologists started prescribing standardized extracts in the 1960s. France approved Permixon, the standardized extract, in 1980. It is one of the most-prescribed medications for BPH in France, Germany, and Italy.
What the research shows
- Carraro et al., 1996. A six-month head-to-head trial of standardized saw palmetto vs. finasteride (Proscar) in 1,098 men. Conclusion: saw palmetto was equivalent to finasteride for symptom relief, with significantly fewer sexual side effects.
- Cochrane review, 2002. 21 trials, 3,139 men. Conclusion: saw palmetto improves urinary symptoms and flow measures, with mild and infrequent adverse events.
- Vela-Navarrete et al., 2018 review. 27 randomized trials, 5,800+ men. Conclusion: standardized saw palmetto extract (specifically the lipidosterolic CO₂ extract used in Permixon) is effective for moderate symptomatic BPH and is well-tolerated long-term.
The dose and form matter — a lot
Two kinds of saw palmetto are sold:
- Powdered berry. Cheap, low active compound content. Most US drugstore saw palmetto is this.
- Standardized lipidosterolic CO₂ extract. What the European trials use. What Permixon is made from. Active compounds (free fatty acids and phytosterols) standardized to a known concentration.
Walter's uses 300 mg of CO₂-extracted lipidosterolic saw palmetto — the same form prescribed in Europe as Permixon and used in the standardized clinical trials cited above. Most US supplements use 160 mg of powdered berry — which has a fraction of the active compounds.
If you've taken saw palmetto before and it didn't work, this is usually why.
Pygeum — the partner
Pygeum africanum is the bark of an African evergreen. French and Italian urologists have been prescribing it for BPH since the late 1960s. It's typically paired with saw palmetto in European formulas, where the combination is referred to as phytotherapeutic synergy — they appear to work along complementary pathways on the same problem.
What the research shows
- Wilt et al., 2002 (Cochrane review). 18 randomized trials, ~1,562 men. Conclusion: pygeum significantly improved urological symptoms and flow measures vs. placebo, with no major adverse effects.
- Multiple smaller trials have shown improvements in urinary urgency, nocturia frequency, and post-void residual volume in men with BPH.
Walter's uses 200 mg of standardized pygeum bark extract — within the range used in European clinical practice (100–200 mg/day).
The supporting cast
Pumpkin seed extract — 100 mg
Studied at the University of Cologne for nighttime bladder symptoms. Traditional use across Eastern Europe for prostate health stretches back generations. Modern research supports a modest effect on lower urinary tract symptoms when used adjunctively.
Stinging nettle (Urtica dioica) — 50 mg
Traditional European herbal. Useful as an adjunct in combination formulas, less impressive as a standalone. Often paired with saw palmetto in studies; combination effects appear additive.
Lycopene — 10 mg
Carotenoid from tomato. The most-studied antioxidant in prostate tissue. Multiple cohort studies suggest dietary lycopene intake correlates with prostate health markers.
Grape seed extract — 100 mg
Source of oligomeric proanthocyanidins (OPCs). Antioxidant and circulatory support; helps the supporting cast do its work.
Boron — 10 mg
Trace mineral with research links to healthy prostate tissue and hormone metabolism. Used at supportive doses in many European prostate formulas.
Vitamin E — 25 mg | Vitamin B6 — 13.8 mg
Standard cofactors in the European clinical formulations. Not the heroes — but they earn their keep.
What's not in Walter's, and why
- No proprietary blends. Every ingredient is listed at its actual dose. We don't hide low-dose extracts behind 'blend' totals.
- No magnesium stearate. Common flow agent that we don't need.
- No titanium dioxide. Common whitening agent now banned in the EU as a food additive.
- No artificial colors or flavors. The capsule is gelatin. The filler is brown rice flour. That's it.
- No melatonin. Walter's is not a sleep aid. It's a prostate formula. Better sleep follows from fewer trips, not from sedation.
How to talk to your urologist
Bring a bottle to your next appointment. A urologist who looks at the label takes thirty seconds to evaluate it. If you're on Flomax, Avodart, or any prescription for BPH, ask whether you can trial Walter's alongside or instead — that's a conversation between you and your doctor, not us.
If you have a PSA test scheduled, tell your urologist you're taking Walter's before the blood draw, not after. Saw palmetto can modestly affect PSA readings.
Citations
Carraro JC et al. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia. Prostate. 1996;29(4):231-240.
Wilt T et al. Pygeum africanum for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2002;(1):CD001044.
Wilt T et al. Saw palmetto extracts for treatment of benign prostatic hyperplasia. JAMA. 1998;280(18):1604-1609.
Vela-Navarrete R et al. Efficacy and safety of a hexanic extract of Serenoa repens for the treatment of LUTS related to BPH. BJU Int. 2018;122(6):1049-1065.